Cigna's PBM Express Scripts sues the FTC, seeking retraction of drug-cost report
Cigna Group's pharmacy benefit manager Express Scripts on Tuesday sued the U.S. Federal Trade Commission, alleging that the agency's July report on the PBM industry was biased and defamatory and asking the court to order the FTC to withdraw the report.
Cigna Demands FTC Retraction in Escalating Drug-Price Fight
One of the country's biggest pharmacy-benefit managers, Cigna Group's CI 0.58%increase; green up pointing triangle Express Scripts, sued the Federal Trade Commission, demanding a retraction of a recent report critical of the companies that negotiate drug spending.
Cigna's Health Benefits Unit Launches a New E-Treatment Option
CI's new launch, a new E-Treatment option, is expected to improve patient satisfaction and operational efficiency.
Cigna Stock Gains 26% in a Year: What Lies Ahead for Investors?
CI benefits from improved premiums resulting from an extensive customer base. Buyouts and adequate operating cash flows are other tailwinds.
Why Cigna (CI) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
If You Can Buy Only 1 Dividend Stock, Make It One of These 3 Income Stars
Dividends are an investor's best friend. While it is a well-known fact the S&P 500 has returned on average 10.5% annually since its inception in 1957, less known is that dividends account for 85% of the index's cumulative total return.
The Cigna Group (CI) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
The Cigna Group (NYSE:CI ) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 10:45 AM ET Company Participants David Cordani - Chairman and CEO Conference Call Participants Erin Wright - Morgan Stanely Erin Wright Good morning, everyone. Welcome to the Morgan Stanley Healthcare Conference.
Cigna to remove AbbVie's Humira from some drug reimbursement lists next year
Cigna said on Monday it will remove AbbVie's blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey biosimilar versions of the medicine instead.
Here's Why Cigna (CI) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The 3 Best Bargain Stocks to Buy in August 2024
Since July 16, volatility in the markets has increased. Stocks have entered correction territory, with the Nasdaq 100 down 13% from its peak.
Cigna (CI) Q2 Earnings Top on Specialty Business Strength
Cigna's (CI) Q2 results reflect new client wins in the Evernorth Health Services unit, partly offset by elevated pharmacy costs. It continues to expect adjusted EPS of at least $28.40 for 2024.
The Cigna Group (CI) Q2 2024 Earnings Call Transcript
The Cigna Group (NYSE:CI ) Q2 2024 Earnings Conference Call August 1, 2024 8:30 AM ET Company Participants Ralph Giacobbe - SVP of IR David Cordani - Chairman and CEO Brian Evanko - CFO, and President and CEO, Cigna Healthcare Eric Palmer - President and CEO, Evernorth Health Services Conference Call Participants Justin Lake - Wolfe Research Lisa Gill - JPMorgan A.J. Rice - UBS Andrew Mok - Barclays Scott Fidel - Stephens Ryan Langston - TD Cowen Josh Raskin - Nephron Research George Hill - Deutsche Bank Erin Wright - Morgan Stanley Stephen Baxter - Wells Fargo Dave Windley - Jefferies Jessica Tassan - Piper Sandler Lance Wilkes - Bernstein Operator Ladies and gentlemen, thank you for standing by for the Cigna Group Second Quarter 2024 Results Review.
